cgp-74588 and Rectal-Neoplasms

A 63-year-old woman underwent living donor liver transplantation for hepatic metastases of an extragastrointestinal stromal tumor (EGIST) originating from the rectovaginal space. Due to a multifocal extrahepatic tumor recurrence, treatment with imatinib mesylate was started after extensive pharmacokinetic studies to rule out possible interactions with immunosuppressives. We performed several re- resections for EGIST recurrence thereafter. At the last follow-up, 17 years after primary tumor resection and 10 years after living donor liver transplantation, the patient is symptom-free under immunosuppressive and imatinib mesylate treatments with a 2-cm stable recurrent pararectal EGIST. To our knowledge, this is the only report published on a patient who underwent transplantation for hepatic EGIST metastases with a posttransplantation follow-up of 10 years and the first report on living donor liver transplantation for metastasized EGIST. This is the first description of pharmacokinetics of imatinib and its main active metabolite CGP74588 in a liver transplant recipient.

Topics: Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Living Donors; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Rectal Neoplasms; Time Factors; Treatment Outcome; Vaginal Neoplasms